2024-11-04 - Analysis Report
##  Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines, vaccines, and animal health products. 

**1. Performance Comparison:**

* **Cumulative Return:** MRK has delivered a cumulative return of 58.02% compared to 131.78% for the S&P 500 (VOO). This puts MRK's performance at a significant lag of **-73.76%**.
* **Relative Performance:** MRK's performance is currently in the **11.92nd percentile** of its historical performance against VOO, indicating a relatively weak performance compared to its historical trend.
* **Alpha & Beta Analysis:** MRK exhibits fluctuating Alpha and Beta values, suggesting inconsistent performance relative to the market. While showing a strong alpha in 2018, the company has struggled in recent years. 
    * 2023 and 2024 have seen negative alpha and beta, indicating underperformance compared to the market.

**2. Recent Price Movement:**

* **Closing Price:** $101.88
* **5-Day Moving Average:** $103.4
* **20-Day Moving Average:** $107.14
* **60-Day Moving Average:** $112.63

MRK is currently trading below all three moving averages, indicating a potential downtrend. However, the 5-day moving average is relatively close to the current price, suggesting potential for a short-term rebound.

**3. Technical Indicators:**

* **RSI:** 23.6 – Indicates oversold conditions, potentially suggesting a short-term bounce. 
* **PPO:** -0.35 – Negative PPO value suggests a downtrend.
* **Delta_Previous_Relative_Divergence:** -10.21 (-), indicating a recent short-term decline.
* **Expected Return:** 0.0% – This indicates a potential for a long-term return similar to the S&P 500, not accounting for potential alpha or beta.

**4. Recent Earnings & Outlook:**

| Date     | EPS    | Revenue     |
|----------|--------|-------------|
| 2024-08-05 | 2.15   | $16.11 B    |
| 2024-05-03 | 1.88   | $15.78 B    |
| 2023-11-03 | 1.87   | $15.96 B    |
| 2023-08-07 | -2.35  | $15.04 B    |
| 2024-08-05 | -2.35  | $15.04 B    |

The most recent earnings for 2024-08-05 showed an EPS of 2.15, which is positive compared to the previous quarter. While revenue continues to be consistent, the overall trend is flat with no significant growth.

**5. Financial Information:**

* **Revenue & Profitability:** MRK demonstrates consistent revenue and high profit margins.
* **Capital & Profitability:** The company has strong equity, with ROE fluctuating in recent quarters. The negative ROE for 2023 Q4 and Q2 is a concern, possibly indicating challenges in maximizing shareholder returns.

**6. News & Recent Issues:**

* **Earnings News:** Recent earnings releases have focused on the company's performance in various sectors like Keytruda and Gardasil. However, no significant news regarding the company's future prospects or potential market disruptions has been reported.
* **Analyst Opinions:**
    * **Finbold**: Analyst reports are currently mixed, with some analysts bullish on MRK due to its strong portfolio and growth potential in Keytruda, while others remain cautious due to the flat revenue growth and potential competition in the pharmaceutical market.

**7. Overall Analysis:**

MRK's performance has lagged behind the S&P 500 in recent years, and although the recent earnings were positive, the overall trend remains flat. Technical indicators suggest potential for short-term rebounds, but long-term prospects remain uncertain.  The high profit margins and strong equity are positive, but the volatile ROE and inconsistent performance relative to the market raise concerns. 

**8. Investment Recommendations:**

* **Short-Term:** The oversold conditions and recent price decline suggest a potential for short-term rebound. However, the long-term outlook remains unclear.
* **Long-Term:** MRK's strong portfolio and potential for growth in Keytruda offer potential for long-term gains, but the lack of significant revenue growth and competition in the pharmaceutical market are concerning.

**Overall, MRK's current performance and future prospects are mixed. It is important to consider both the positive aspects, such as its strong portfolio and equity, and the negative aspects, such as the lack of significant growth and inconsistent performance, when making investment decisions.**